UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up spending, Mercer's latest survey reveals.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.